Skip to main content


News

JCP Editors, June 26, 2020
Researchers designed a risk prediction score for early severe infection in patients with multiple myeloma regardless of…
JCP Editors, June 25, 2020
A retrospective, population-based study compared the long-term outcomes of patients with MCL who were treated with four…
JCP Editors, June 22, 2020
In patients with relapsed or refractory multiple myeloma and soft -tissue plasmacytomas, an isatuximab-based regimen…
JCP Editors, June 18, 2020
Researchers demonstrated improved health-related quality of life for patients with heavily pretreated or renally…
JCP Editors, June 18, 2020
Recent research suggests cytologic and genetic alteration factors that are significant drivers of progressive disease…
JCP Editors, June 17, 2020
Researchers presenting at the European Hematology Association Virtual Meeting described the cumulative incidence of…
JCP Editors, June 16, 2020
Patients with relapsed or refractory non-GCB DLBCL and high PAX5 expression or CD79B mutation have a higher likelihood…
JCP Editors, June 15, 2020
A study presented at the European Hematology Association Virtual Meeting showed that BTK inhibitor therapy is effective…
Back to Top